Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 8, 2019
Reporting Period: Quarterly period ended March 31, 2019
Business Context: The filing announces the issuance of a press release detailing financial results for the quarter ended March 31, 2019. The company is incorporated in Virginia and trades on the NASDAQ Global Select Market under the symbol "COLL".
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) but does not contain specific financial data. Consequently, the following metrics are not available in this filing text:
- Revenue: Not provided.
- Profit/Loss: Not provided.
- Cash Flow: Not provided.
- Margins: Not provided.
- Debt and Liquidity: Not provided.
Material Changes
The filing text does not provide specific numerical comparisons or descriptions of material changes versus the prior comparable period. It only confirms that results for the quarter ended March 31, 2019, were announced.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that management commentary and detailed results are contained in the attached press release (Exhibit 99.1), which is furnished but not filed as part of this specific text block.
Guidance and Outlook: No forward-looking guidance or outlook is present in the provided text.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 8, 2019) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the financial results for the quarter ended March 31, 2019, as they are not embedded in the 8-K body text.
- Check for any updated guidance or operational milestones mentioned in the full press release.